Precision Business Insights

Research Reports

Photopheresis Devices Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis and Forecast 2018 to 2024

Photopheresis Devices Market By Product Type (Open System, Closed System), By Disease Indication (Autoimmune diseases, Graft versus host disease, Cutaneous T-cell lymphoma, Transplant rejections), By Distribution Channel (Hospitals, Ambulatory Care, Others), and Geography.


Market Outline: Photopheresis Devices Market


Photopheresis is a form of apheresis in which small amount of the blood is treated with photosensitizing agent. Photopheresis is popular for its therapeutic option used in various autoimmune diseases, organ transplantation such as kidney and liver advanced cutaneous T-cell lymphoma and acute and chronic graft versus host disease (GVHD). U.S. FDA in 1988, has first approved extracorporeal photopheresis (ECP) which is now known as extracorporeal photo immunotherapy, as leukapheresis-based therapeutic procedure. In Photopheresis, the white blood cells are collected after being exposed to the UVA radiation, 8-MOP. As far as devices of photopheresis are concerned, many open and closed systems available in the market, of which only closed systems are approved by the U.S. FDA due to its lesser risk of contamination, flaws and infection during reinfusion.


Market Dynamics: Photopheresis Devices Market


The increasing prevalence of autoimmune diseases and rising number of organ transplant cases are expected to drive the photopheresis devices market. The safer and effective treatment promised by the introduction of these devices is one of the major factor expected to drives photopheresis devices market. The increased government reimbursement policies and private health insurance is playing a key role in the growth of the market. The awareness about ECP therapy will boost the market. However, the higher cost, time, constant therapy sessions are expected to hinder the market. The availability of lesser number of ECP therapy centers is expected to dampen the market.


Global photopheresis devices market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over 2018 to 2024.


Market Scope: Photopheresis Devices Market

Photopheresis devices market is segmented based on the product type, technology, disease indication, and distribution channel


Based on the product type, the market is segmented into the following:

  • Open System
  • Closed system


Based on the disease indication, the market is segmented into the following:

  • Autoimmune diseases
  • Graft versus host disease
  • Cutaneous T-cell lymphoma
  • Transplant rejections


Based on the distribution channel, the market is segmented into the following:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others


Regional Analysis:  Photopheresis Devices Market


Geographically, global photopheresis devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America photopheresis devices market is dominant in the photopheresis devices market. The huge reimbursements provided by the government for various treatments such as GVHD, CTL, and lung transplantations which is treated by ECP therapy is a key factor expected to drive the market. However, Asia Pacific is expected to dominate the market due to increased initiatives in terms of the expansion of the photopheresis products market over the forecast period. The increasing count of photopheresis centers is expected to drive the market. The faster regulatory approvals is expected fuel the market in future.


Competition Assessment: Photopheresis Devices Market

  • Macopharma (FRANCE)
  • Haemonetics Corporation (U.S)
  • Fresenius Kabi AG (Germany)
  • Terumo Corporation (Japan)
  • Mallinckrodt Pharmaceuticals (UK)


Notable Market Developments:

  • In August 2016, Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced that Switzerland’s Federal Department of Home Affairs (FDHA) has approved reimbursement of Extracorporeal Photopheresis (ECP) treatment for patients in Switzerland with Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation. Mallinckrodt Pharmaceuticals provides ECP therapy through its THERAKOS therapeutic platforms, including the latest generation THERAKOS CELLEX Photopheresis System


Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Macopharma (FRANCE)
Haemonetics Corporation (U.S)
Fresenius Kabi AG (Germany)
Terumo Corporation (Japan)
Mallinckrodt Pharmaceuticals (UK)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

Ask An Analyst